Get started
Krsnaa Diagnostics LimitedKrsnaa Diagnostics LimitedKrsnaa Diagnostics Limited

Krsnaa Diagnostics Limited

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsETFs

Trade ideas

KRSNAA DIAGOSTICS techno-funda analysisKrsnaa Diagnostics Ltd. is one of India's largest diagnostic service providers, operating diagnostic centers across public-private partnerships (PPPs) and private hospital networks. The company offers radiology, pathology, and teleradiology solutions. With an expanding national footprint and tie-ups with state governments, the stock is currently trading at ₹785.50, showing technical signs of accumulation after a prolonged corrective phase. Krsnaa Diagnostics Ltd. – FY22–FY25 Snapshot Sales – ₹415 Cr → ₹489 Cr → ₹574 Cr → ₹642 Cr – Consistent top-line growth driven by PPPs Net Profit – ₹43.6 Cr → ₹54.2 Cr → ₹64.9 Cr → ₹82.7 Cr – Strong margin profile with cost control and volume Company Order Book – Moderate → Strong → Strong → Strong – Robust pipeline from state diagnostic projects Dividend Yield (%) – 0.00% → 0.00% → 0.00% → 0.00% – No payouts; reinvestment-led growth strategy Operating Performance – Moderate → Moderate → Strong → Strong – Operating leverage kicking in Equity Capital – ₹31.78 Cr (constant) – Stable equity base, no dilution Total Debt – ₹123 Cr → ₹112 Cr → ₹102 Cr → ₹93 Cr – Deleveraging consistently Total Liabilities – ₹435 Cr → ₹456 Cr → ₹478 Cr → ₹505 Cr – Aligned with expansion and capacity build-up Fixed Assets – ₹155 Cr → ₹170 Cr → ₹186 Cr → ₹205 Cr – Gradual asset base expansion to support lab network Latest Highlights FY25 net profit rose 27.4% YoY to ₹82.7 Cr; revenue increased 11.8% to ₹642 Cr EPS: ₹26.02 | EBITDA Margin: 24.7% | Net Margin: 12.9% Return on Equity: 13.91% | Return on Assets: 7.49% Promoter holding: 27.34% | Dividend Yield: 0.00% New PPP contracts in Maharashtra and West Bengal began contributing to volumes Focus on expanding radiology-led diagnostics and digital teleradiology infrastructure Technical Snapshot Krsnaa Diagnostics is trading at ₹785.50 with an RSI of 50.33, indicating neutral momentum with signs of base formation. Price is consolidating just above a key support zone around ₹728.45. Volume is gradually increasing. If buying interest continues, potential medium-term targets emerge near ₹944.60, ₹1,031.30, and ₹1,141.70, based on Fibonacci retracement projections. Business Growth Verdict Yes, Krsnaa Diagnostics is expanding steadily with a scalable and asset-light model Margins and profits are improving on the back of volume growth Balance sheet is strengthening with steady debt reduction Strategic growth focused on underserved geographies via PPPs and digital health infrastructure Final Investment Verdict Krsnaa Diagnostics presents an attractive scalable opportunity in India’s expanding diagnostics ecosystem. With sustained earnings momentum, rising efficiency, and a robust public-private client base, the company is building a dependable long-term platform. Although the promoter stake is modest and dividends are absent, the earnings quality, healthcare tailwinds, and improving operating leverage position the stock as a strong compounder candidate in the diagnostics segment.
NSE:KRSNAALong
by TechnicalAnalystSucrit
KRSNAA DIAGOSTIC 1WKRSNAA DIAGOSTIC, the stock has shown a strong bullish signal. The breakout from the cup and handle pattern suggests that there's a potential for a significant price increase. However, to confirm this and reduce risk, it's recommended to wait for a retest. A retest occurs when the price temporarily retraces back to the previously broken resistance level (now support) before resuming its upward movement. This retest can provide a buying opportunity at a potentially lower price point. I'm not a SEBI-registered analyst. All posts and levels shared are just for educational purposes. I'm not responsible for any losses or profits. No claims, all rights reserved
NSE:KRSNAALong
by saimandali
1